AbbVie, Inc. (ABBV)
285.64
+0.45
(+0.16%)
USD |
NYSE |
Oct 23, 16:00
285.27
-0.37
(-0.13%)
After-Hours: 20:00
AbbVie Enterprise Value : 569.05B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 569.05B |
| October 22, 2026 | 568.25B |
| October 21, 2026 | 567.56B |
| October 20, 2026 | 575.12B |
| October 19, 2026 | 563.82B |
| October 16, 2026 | 568.66B |
| October 15, 2026 | 565.09B |
| October 14, 2026 | 565.23B |
| October 13, 2026 | 549.11B |
| October 12, 2026 | 561.06B |
| October 09, 2026 | 552.84B |
| October 08, 2026 | 545.69B |
| October 07, 2026 | 543.81B |
| October 06, 2026 | 535.56B |
| October 05, 2026 | 533.92B |
| October 02, 2026 | 528.72B |
| October 01, 2026 | 523.61B |
| September 30, 2026 | 526.55B |
| September 29, 2026 | 529.55B |
| September 28, 2026 | 534.84B |
| September 25, 2026 | 531.41B |
| September 24, 2026 | 532.79B |
| September 23, 2026 | 532.71B |
| September 22, 2026 | 532.94B |
| September 21, 2026 | 531.65B |
| Date | Value |
|---|---|
| September 18, 2026 | 530.74B |
| September 17, 2026 | 530.84B |
| September 16, 2026 | 528.17B |
| September 15, 2026 | 529.11B |
| September 14, 2026 | 526.87B |
| September 11, 2026 | 518.65B |
| September 10, 2026 | 514.90B |
| September 09, 2026 | 507.68B |
| September 08, 2026 | 503.91B |
| September 04, 2026 | 517.48B |
| September 03, 2026 | 524.11B |
| September 02, 2026 | 526.78B |
| September 01, 2026 | 523.72B |
| August 31, 2026 | 517.41B |
| August 28, 2026 | 515.75B |
| August 27, 2026 | 520.47B |
| August 26, 2026 | 528.86B |
| August 25, 2026 | 533.97B |
| August 24, 2026 | 531.73B |
| August 21, 2026 | 532.50B |
| August 20, 2026 | 526.97B |
| August 19, 2026 | 534.29B |
| August 18, 2026 | 521.83B |
| August 17, 2026 | 506.65B |
| August 14, 2026 | 505.11B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 214.93B |
| Biogen, Inc. | 44.10B |
| Amgen, Inc. | 280.78B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
| REGENXBIO, Inc. | 506.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.604B |
| Revenue (Quarterly) | 16.99B |
| Total Expenses (Quarterly) | 13.39B |
| EPS Diluted (Quarterly) | 2.033 |
| Gross Profit Margin (Quarterly) | 74.71% |
| Profit Margin (Quarterly) | 21.21% |
| Earnings Yield | 1.24% |
| Operating Earnings Yield | 4.35% |
| Normalized Earnings Yield | 2.819 |